TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT06564324: A Phase 3 Multicenter Open-label Study of Taletrectinib Versus a Standard of Care ROS1-Tyrosine Kinase Inhibitor (Crizotinib) in TKI-Naïve Patients With ROS1-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer (TRUST-III)

Sponsor: Nuvation Bio Inc. · Phase: PHASE3 · Area: ONCOLOGY · Target Enrollment: 194 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$721,644

Rescue Site Savings

+$459,228

Unlock Full NCT06564324 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06564324 Rescue Dossier →